Polygenic risk score was not clearly linked with cognitive prognosis prediction performance in humans (Incremental contribution in PRISM-AD; Benjamini-Hochberg correction) (No increment met BH q < 0.05).
“No PRISM-AD PRS increment met BH q < 0.05.”
HumansIncremental contribution in PRISM-AD; Benjamini-Hochberg correction
Clinical journal of the American Society of Nephrology : CJASN·
Prediction of metabolic, cardiovascular, autoimmune, and neurological diseases
↑upin humans1
1 study
Polygenic risk score is linked with better prediction of metabolic, cardiovascular, autoimmune, and neurological diseases in humans (combined with clinical risk models).
“Genetic information provided the largest predictive gains in metabolic, cardiovascular, autoimmune, and neurological disease”
Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·
Associations
144
Coronary artery disease
↑upin humans15HR 1.37–7.1
15 studies
Polygenic risk score is associated with coronary artery disease in humans (Q4 versus Q1 polygenic risk score; association attenuated with age) (Q4-vs-Q1 HR 7.1 at age 45 and 2.5 at age 70; -0.18/yr).
“For CAD, the observed Q4-vs-Q1 PRS hazard ratio fell from 7.1 at age 45 to 2.5 at age 70 (-0.18/yr);”
HumansQ4 versus Q1 polygenic risk score; association attenuated with age
Polygenic risk score predicts coronary artery disease in individuals with chronic kidney disease, accounting for PREVENT risk factors.
“A PRS of CHD was significantly associated with a 21% hazard of CHD in the PRS+PREVENT risk model (95% CI, [1.06-1.39], 2-sided Wald test P =5.5×10 -3 ).”
Humansin individuals with chronic kidney disease, accounting for PREVENT risk factors10-year
Polygenic risk score is associated with coronary artery disease in humans (Adjusted subdistribution HR 1.37 per 1 SD; 95% CI 1.21–1.55).
“Each 1-SD increase in the principal component-adjusted PRS was associated with the primary endpoint (adjusted subdistribution hazard ratio, 1.37; 95% CI, 1.21-1.55; p < 0.001).”
HumansWithout baseline coronary artery disease; per 1-SD increase in principal component-adjusted polygenic risk scoreMedian follow-up of 6.8 yearsn = 2,067
Polygenic risk score predicts coronary artery disease in humans (combined with age and sex) (AUC 0.910).
“the PRS models demonstrated strong predictive performance for coronary artery disease, atherosclerosis, and ischemic stroke, with area under the curve values of 0.910, 0.926, and 0.854, respectively.”
Polygenic risk score is associated with coronary artery disease in humans (nonobstructive CAD on coronary angiography) (OR 1.26, 95% CI 1.14-1.39).
“increasing levels of the polygenic risk score were strongly associated with increased prevalence of nonobstructive and obstructive CAD on coronary angiography (odds ratio, 1.26 [95% CI, 1.14-1.39]”
Polygenic risk score is linked with a higher risk of coronary artery disease in humans (positive family history and high polygenic risk score) (OR: 3.26; 95% CI: 3.03 - 3.50).
Polygenic risk score is linked with a higher risk of type 2 diabetes in humans (African Americans, highest vs lowest tertile) (OR = 1.61; 95% CI:1.22-2.12).
“African Americans had a higher magnitude of incident T2DM risk for the high-risk PRS alone (OR = 1.61; 95% CI:1.22-2.12) than European Americans”
HumansAfrican Americans, highest vs lowest tertilen = 1,205
Polygenic risk score predicts type 2 diabetes in humans (for diabetes onset and complications).
“Polygenic risk scores (PRS) can support risk stratification for diabetes onset and complications, but their implementation in Asian populations is limited by reduced cross-population transferability.”
Polygenic risk score is linked with a higher risk of prostate cancer in humans (multi-ancestry cohort) (OR 1.61 to 2.19).
“In ancestry-stratified testing, the PRS showed strong associations with prostate cancer risk, with odds ratios (ORs) per standard deviation (SD) increase ranging from 1.61”
Polygenic risk score predicts prostate cancer in humans (Asian men in the highest polygenic risk score decile) (4- to 5-fold increased risk in the highest decile).
“population-specific PRS models effectively stratify prostate cancer risk in Asian men, with individuals in the highest decile showing a 4- to 5-fold increased risk.”
ReviewAsian men in the highest polygenic risk score decilemales
medRxiv : the preprint server for health sciences·Preprint
Polygenic risk score predicts Alzheimer's disease in humans across ancestries (AFR: P =2.04×10 − 26 ; AMR: P =4.57×10 −21 ; EAS: P =6.21×10 −40 ; EUR: P =7.90×10 −187).
“Top-performing PRS were effective at stratifying AD risk across ancestries”
medRxiv : the preprint server for health sciences·Preprint
Polygenic risk score is linked with a higher risk of Alzheimer's disease in humans (OR 1.14-1.52 per SD).
“The PRS was significantly associated with AD in European ancestry, African American, Caribbean Hispanic and Native American Hispanic groups with adjusted odds ratios between 1.14 and 1.52”
Polygenic risk score is associated with Alzheimer's disease in humans (high vs low PRS and TRS values) (2.5-fold in ADNI and 3.4-fold in SNUBH).
“Individuals with high PRS and TRS values showed larger odds ratios for AD, 2.5-fold in ADNI and 3.4-fold in SNUBH, compared to those with low PRS and TRS values.”
Polygenic risk score predicts breast cancer in women of African ancestry (AUC 0.57 (95% CI: 0.56–0.59)).
“Overall, PRS models demonstrated modest predictive performance for breast cancer risk in women of African ancestry, with a pooled AUC of 0.57 (95% CI: 0.56–0.59”
Polygenic risk score is associated with breast cancer in humans (Chinese women; per 1 SD increase in PRS) (OR 1.64 per 1 SD increase).
“PRSLRR achieved robust and stable performance across cohorts, yielding an area under the receiver operating characteristic curve (AUC) of 0.633 and an OR of 1.64 per 1 SD increase.”
HumansChinese women; per 1 SD increase in PRSfemales
Polygenic risk score is linked with a lower risk of breast cancer in humans (≤ 10th percentile) (OR 0.6, p = 1.6 × 10−3).
“High PRS (≥ 90th percentile) was associated with increased risk (OR 1.8, p = 3.3 × 10−8) and low PRS (≤ 10th percentile) with reduced risk (OR 0.6, p = 1.6 × 10−3) of breast cancer.”
Polygenic risk score is linked with a higher risk of breast cancer in humans (≥ 90th percentile) (OR 1.8, p = 3.3 × 10−8).
“High PRS (≥ 90th percentile) was associated with increased risk (OR 1.8, p = 3.3 × 10−8) and low PRS (≤ 10th percentile) with reduced risk (OR 0.6, p = 1.6 × 10−3) of breast cancer.”
Polygenic risk score is linked with a higher risk of breast cancer in humans (highest vs mid PRS deciles) (approximately three times higher risk, highest vs mid deciles).
“Individuals in the highest PRS decile had approximately three times higher risk compared to those in the mid deciles.”
Polygenic risk score is associated with breast cancer in humans (Black women) (HR1-SD 1.15 (95% CI 0.96-1.38)).
“A higher PRS was associated with a higher breast cancer risk among White (HR1-SD, 1.48; 95% CI, 1.34-1.65) and Black (HR1-SD, 1.15; 95% CI, 0.96-1.38) women.”
Polygenic risk score is linked with a higher risk of breast cancer in humans (White women) (HR1-SD 1.48 (95% CI 1.34-1.65)).
“A higher PRS was associated with a higher breast cancer risk among White (HR1-SD, 1.48; 95% CI, 1.34-1.65) and Black (HR1-SD, 1.15; 95% CI, 0.96-1.38) women.”
Polygenic risk score is linked with a higher risk of cardiovascular disease in humans.
“These diverging BP trajectories also seem to affect cardiovascular and renal disease risk, with increased risk observed among those in the top decile”
“PRS can identify individuals with elevated lifelong CVD risk, although their current clinical utility is primarily as risk-enhancing markers rather than standalone diagnostic tests.”
Polygenic risk score is linked with a higher risk of colorectal cancer in humans (IV-weighted PRS, highest versus lowest tertile, mutually adjusted) (OR = 1.50; 95% CI, 1.10-2.06).
“IV-weighted PRS: OR = 1.50; 95% CI, 1.10-2.06”
HumansIV-weighted PRS, highest versus lowest tertile, mutually adjusted
Polygenic risk score is linked with a higher risk of colorectal cancer in humans (HR 2.40, 95% CI 1.99 to 2.89).
“The highest quintile of the polygenic risk score was associated with a 2.4-fold increase in CRC risk compared with the lowest quintile (Q5 vs Q1: hazard ratio [HR] = 2.40”
Polygenic risk score predicts age-related macular degeneration in humans (prediction model including LDpred2-based PRS + covariates) (AUC 0.82 (95% CI 0.79-0.85)).
“A prediction model including LDpred2-based PRS + covariates had an AUC of 0.82 (95% CI 0.79-0.85) and performed better than covariates-only model (P = 5.1 × 10−9).”
Humansprediction model including LDpred2-based PRS + covariates
Polygenic risk score is linked with a higher risk of age-related macular degeneration in humans (top 5% PRS vs bottom quartile) (1.40-fold, 95% CI 1.04-1.89, p = 0.025).
“Individuals with the top 5% PRS had a 1.40-fold higher AMD risk compared with that of individuals with a PRS in the bottom quartile (95% CI = 1.04-1.89, p = 0.025).”
Polygenic risk score is linked with a higher risk of age-related macular degeneration in humans (highest quantile vs lowest reference quantile) (OR = 35.13, 95% CI: (7.9; 156.1), p < 0.001).
“The patients in the highest quantile had a significantly higher relative risk of developing AMD than those in the lowest reference quantile (OR = 35.13, 95% CI: (7.9; 156.1), p < 0.001).”
Humanshighest quantile vs lowest reference quantile
Polygenic risk score is linked with a higher risk of atherosclerotic cardiovascular disease in humans (borderline PREVENT scores (5.0-7.5%)) (OR 1.9).
“observed 10y ASCVD rate moved from 4.8% (4.0-5.7%) to 8.8% (7.7-10.0%) in low (bottom 20%) versus high (top 20%) PRS individuals, an odds ratio of 1.9”
Polygenic risk score is linked with a higher risk of atherosclerotic cardiovascular disease in humans (highest tertile compared to lowest tertile) (RR 1.59, 95% CI 1.16–2.17).
“The high-risk PRS increased ASCVD risk by 59% (Risk Ratio=1.59;95% Confidence Interval:1.16-2.17) in the highest tertile for AAs”
Humanshighest tertile compared to lowest tertilen = 1,606
medRxiv : the preprint server for health sciences·Preprint
Polygenic risk score predicts atherosclerotic cardiovascular disease in European populations.
“Polygenic risk scores (PRS), which quantify this inherited susceptibility, have demonstrated strong predictive performance in European populations, with accumulating evidence supporting their use in clinical practice.”
Polygenic risk score predicts dementia in humans (C+T method with 15 SNPs) (HR 1.18, 95% CI: 1.08-1.28).
“We found comparable associations between dementia and PRS when comparing a C+T method with only 15 SNPs and PRS derived from Bayesian models that include > 800,000 SNPs (HR5e-08 = 1.18, 95% CI: 1.08-1.28;”
Journal of neurology, neurosurgery, and psychiatry·
Polygenic risk score is linked with a higher risk of dementia in humans (high versus low polygenic risk score tertile) (1.4-fold (high vs low tertile), CI 1.04-1.76).
“High PRS tertile was associated with a 1.4-fold dementia risk versus low (CI 1.04-1.76, p = 0.02)”
Humanshigh versus low polygenic risk score tertile
Polygenic risk score is associated with screening recommendations in humans (40 were advised to begin biennial screening before age 50).
“Polygenic risk score testing may influence current screening recommendations and contribute to more personalized risk-based breast cancer screening strategies.”
Across two health-record cohorts, age-varying genetic effects improved one-year prediction for 27 of 28 diseases compared with a model that kept those effects fixed.Across two health-record cohorts, age-varying genetic effects improved one-year prediction for 27 of 28 diseases compared with a model that kept those effects fixed.
Adding 250 chemical markers improved risk models beyond standard clinical measures in an observational study of 54,933 Kaiser Permanente biobank participants.Adding 250 chemical markers improved risk models beyond standard clinical measures in an observational study of 54,933 Kaiser Permanente biobank participants.